India's Medical Technology Sector Gets First Dedicated Investment Fund
In a landmark development for India's healthcare industry, the medical technology (medtech) sector is poised to receive its first dedicated investment fund. A consortium of investors and industry veterans, spearheaded by Ganesh Sabat, the former CEO of major cardiac stent manufacturer SMT (Sahajanand Medical Technologies), is launching a Rs 1,000 crore growth-stage fund named MedArtha Capital.
Government Support and Strategic Focus
This initiative marks a significant shift, as private equity investors have traditionally focused on the broader healthcare landscape rather than the standalone medtech segment. In another pioneering move, the Indian government is expected to invest approximately Rs 500 crore in the fund under its Research Development and Innovation (RDI) scheme. This scheme, which boasts a Rs 1 lakh crore corpus announced last year, is designed to stimulate investment in research, development, and innovation ecosystems across the country.
MedArtha Capital recently secured approval from the Securities and Exchange Board of India (SEBI) and plans to deploy its capital over the next two to three years. The fund will target 10 to 12 small but high-growth medtech companies, providing them with the necessary financial backing and operational expertise to scale their operations.
Addressing Import Dependence and Building Capabilities
Positioned as a scale-up platform rather than an early-stage pool, MedArtha Capital aims to support companies with revenues in the Rs 30-80 crore range. These firms require capital and strategic guidance to expand their manufacturing capabilities and compete in a market that remains heavily reliant on imports. Key segments targeted by the fund include MRI machines, CT scanners, devices for cathlabs, and neurovascular devices used in treating conditions like stroke and heart failure.
Ganesh Sabat, the founder and managing partner of MedArtha Capital, emphasized that the fund's strategy extends beyond mere financial investment. It includes building contract development and manufacturing capabilities within the medtech sector, an area that is currently non-existent in India. This approach is aligned with the government's 'Make in India' push, aiming to reduce import dependency and foster domestic production of advanced medical equipment.
Fund Structure and Long-Term Vision
MedArtha Capital has an eight-year life cycle and has submitted an application under the RDI scheme. This scheme allows eligible entities to receive investment support of up to 50% of the total fund size, providing a substantial boost to the initiative's financial foundation. The fund's focus on growth-stage companies ensures that it can drive tangible impact by helping established players overcome scalability challenges and enhance their market presence.
The launch of MedArtha Capital represents a critical step forward for India's medtech sector, which has long struggled with limited dedicated funding. By combining private investment with government support, this fund aims to catalyze innovation, strengthen manufacturing infrastructure, and position India as a competitive player in the global medical technology arena. As the fund begins its deployment phase, it is expected to unlock new opportunities for domestic medtech firms, contributing to both economic growth and improved healthcare outcomes across the nation.
